These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15596745)

  • 1. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.
    Sorensen PS; Haas J; Sellebjerg F; Olsson T; Ravnborg M;
    Neurology; 2004 Dec; 63(11):2028-33. PubMed ID: 15596745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
    Hervás-García JV; Ramió-Torrentà L; Brieva-Ruiz L; Batllé-Nadal J; Moral E; Blanco Y; Cano-Orgaz A; Presas-Rodríguez S; Torres F; Capellades J; Ramo-Tello C
    Eur J Neurol; 2019 Mar; 26(3):525-532. PubMed ID: 30351511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL; Zhang ZC; Zhang B; Jiang H; Yu CM; Zhang WJ; Yan X; Wang MX
    Int Immunopharmacol; 2014 Dec; 23(2):546-9. PubMed ID: 25448497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
    Dudesek A; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
    Sorensen PS; Fazekas F; Lee M
    Eur J Neurol; 2002 Nov; 9(6):557-63. PubMed ID: 12453069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.
    Lewańska M; Siger-Zajdel M; Selmaj K
    Eur J Neurol; 2002 Nov; 9(6):565-72. PubMed ID: 12453070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.
    Sharrack B; Hughes RA; Morris RW; Soudain S; Wade-Jones O; Barnes D; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi HA; Farmer S; Frankel JP
    J Neurol Sci; 2000 Feb; 173(1):73-7. PubMed ID: 10675582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis.
    Roed HG; Langkilde A; Sellebjerg F; Lauritzen M; Bang P; Mørup A; Frederiksen JL
    Neurology; 2005 Mar; 64(5):804-10. PubMed ID: 15753413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.